ログイン
言語:

WEKO3

  • トップ
  • ランキング
To
lat lon distance
To

Field does not validate



インデックスリンク

インデックスツリー

メールアドレスを入力してください。

WEKO

One fine body…

WEKO

One fine body…

アイテム

{"_buckets": {"deposit": "f5ee024e-21b6-4636-9862-d764bdab5d48"}, "_deposit": {"id": "26319", "owners": [], "pid": {"revision_id": 0, "type": "depid", "value": "26319"}, "status": "published"}, "_oai": {"id": "oai:nagoya.repo.nii.ac.jp:00026319", "sets": ["2109"]}, "item_9_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2018-08", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "3", "bibliographicPageEnd": "298", "bibliographicPageStart": "289", "bibliographicVolumeNumber": "80", "bibliographic_titles": [{"bibliographic_title": "Nagoya Journal of Medical Science"}]}]}, "item_9_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Neurodegenerative diseases are disorders that are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Recent advancements in the translational research have facilitated extensive insights into the molecular pathophysiology of neurodegenerative diseases. Nonetheless, a myriad of compounds that suppressed the disease progression in cellular and animal models did not exhibit efficacy in clinical trials. Perhaps, various biological, medical, and methodological factors could be attributed to unfavorable results of clinical trials of such disease-modifying therapies. Primarily, the fact that pathological changes at molecular and cellular levels precede the clinical onset by several years underscores a pressing need for the initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This review aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.", "subitem_description_type": "Abstract"}]}, "item_9_identifier_registration": {"attribute_name": "ID登録", "attribute_value_mlt": [{"subitem_identifier_reg_text": "10.18999/nagjms.80.3.289", "subitem_identifier_reg_type": "JaLC"}]}, "item_9_publisher_32": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "Nagoya University Graduate School of Medicine, School of Medicine"}]}, "item_9_relation_43": {"attribute_name": "異版である", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/803.html ", "subitem_relation_type_select": "URI"}}]}, "item_9_select_15": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_select_item": "publisher"}]}, "item_9_source_id_61": {"attribute_name": "ISSN(Online)", "attribute_value_mlt": [{"subitem_source_identifier": "2186-3326", "subitem_source_identifier_type": "ISSN"}]}, "item_9_source_id_7": {"attribute_name": "ISSN(print)", "attribute_value_mlt": [{"subitem_source_identifier": "0027-7622", "subitem_source_identifier_type": "ISSN"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Katsuno, Masahisa"}], "nameIdentifiers": [{"nameIdentifier": "84893", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Sahashi, Kentaro"}], "nameIdentifiers": [{"nameIdentifier": "84894", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Iguchi, Yohei"}], "nameIdentifiers": [{"nameIdentifier": "84895", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Hashizume, Atsushi"}], "nameIdentifiers": [{"nameIdentifier": "84896", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2018-08-28"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "01_Katsuno.pdf", "filesize": [{"value": "308.2 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 308200.0, "url": {"label": "01_Katsuno.pdf", "url": "https://nagoya.repo.nii.ac.jp/record/26319/files/01_Katsuno.pdf"}, "version_id": "690745d6-719e-4da5-9c6e-61437a10982c"}]}, "item_keyword": {"attribute_name": "キーワード", "attribute_value_mlt": [{"subitem_subject": "preclinical", "subitem_subject_scheme": "Other"}, {"subitem_subject": "prodromal", "subitem_subject_scheme": "Other"}, {"subitem_subject": "neurodegenerative disease", "subitem_subject_scheme": "Other"}, {"subitem_subject": "biomarker", "subitem_subject_scheme": "Other"}, {"subitem_subject": "preventive therapy", "subitem_subject_scheme": "Other"}, {"subitem_subject": "disease-modifying therapy", "subitem_subject_scheme": "Other"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "departmental bulletin paper", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Preclinical progression of neurodegenerative diseases", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Preclinical progression of neurodegenerative diseases"}]}, "item_type_id": "9", "owner": "1", "path": ["2109"], "permalink_uri": "https://doi.org/10.18999/nagjms.80.3.289", "pubdate": {"attribute_name": "公開日", "attribute_value": "2018-08-28"}, "publish_date": "2018-08-28", "publish_status": "0", "recid": "26319", "relation": {}, "relation_version_is_last": true, "title": ["Preclinical progression of neurodegenerative diseases"], "weko_shared_id": 3}
  1. C100 医学部/医学系研究科
  2. C100b 紀要
  3. Nagoya journal of medical science
  4. 80(3)

Preclinical progression of neurodegenerative diseases

https://doi.org/10.18999/nagjms.80.3.289
https://doi.org/10.18999/nagjms.80.3.289
a5303159-2732-45ee-9f63-17a2fea61caf
名前 / ファイル ライセンス アクション
01_Katsuno.pdf 01_Katsuno.pdf (308.2 kB)
Item type 紀要論文 / Departmental Bulletin Paper(1)
公開日 2018-08-28
タイトル
タイトル Preclinical progression of neurodegenerative diseases
著者 Katsuno, Masahisa

× Katsuno, Masahisa

WEKO 84893

Katsuno, Masahisa

Search repository
Sahashi, Kentaro

× Sahashi, Kentaro

WEKO 84894

Sahashi, Kentaro

Search repository
Iguchi, Yohei

× Iguchi, Yohei

WEKO 84895

Iguchi, Yohei

Search repository
Hashizume, Atsushi

× Hashizume, Atsushi

WEKO 84896

Hashizume, Atsushi

Search repository
キーワード
主題Scheme Other
主題 preclinical
キーワード
主題Scheme Other
主題 prodromal
キーワード
主題Scheme Other
主題 neurodegenerative disease
キーワード
主題Scheme Other
主題 biomarker
キーワード
主題Scheme Other
主題 preventive therapy
キーワード
主題Scheme Other
主題 disease-modifying therapy
抄録
内容記述 Neurodegenerative diseases are disorders that are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Recent advancements in the translational research have facilitated extensive insights into the molecular pathophysiology of neurodegenerative diseases. Nonetheless, a myriad of compounds that suppressed the disease progression in cellular and animal models did not exhibit efficacy in clinical trials. Perhaps, various biological, medical, and methodological factors could be attributed to unfavorable results of clinical trials of such disease-modifying therapies. Primarily, the fact that pathological changes at molecular and cellular levels precede the clinical onset by several years underscores a pressing need for the initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This review aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.
内容記述タイプ Abstract
出版者
出版者 Nagoya University Graduate School of Medicine, School of Medicine
言語
言語 eng
資源タイプ
資源 http://purl.org/coar/resource_type/c_6501
タイプ departmental bulletin paper
ID登録
ID登録 10.18999/nagjms.80.3.289
ID登録タイプ JaLC
関連情報
関連タイプ isVersionOf
識別子タイプ URI
関連識別子 http://www.med.nagoya-u.ac.jp/medlib/nagoya_j_med_sci/803.html
ISSN(print)
収録物識別子タイプ ISSN
収録物識別子 0027-7622
ISSN(Online)
収録物識別子タイプ ISSN
収録物識別子 2186-3326
書誌情報 Nagoya Journal of Medical Science

巻 80, 号 3, p. 289-298, 発行日 2018-08
著者版フラグ
値 publisher
戻る
0
views
See details
Views

Versions

Ver.1 2021-03-01 11:28:21.115484
Show All versions

Share

Mendeley Twitter Facebook Print Addthis

Cite as

エクスポート

OAI-PMH
  • OAI-PMH JPCOAR
  • OAI-PMH DublinCore
  • OAI-PMH DDI
Other Formats
  • JSON
  • BIBTEX

Confirm


Powered by WEKO3


Powered by WEKO3